Medical Advocates
ARV/HAART
  Therapeutic Strategies

 General Challenges          Directly Administered Therapy       
Starting Therapy               Salvage Therapy      
Switching Therapy            Prevention
Simplification Therapy      Discontinuation of Therapy  
Once-Daily Vs Twice-Daily Regimens    
Intensification Therapy
 Mega-HAART
General Outcome Studies
 Treatment-Experienced Patients: General Studies
Advanced HIV Disease
Intermittent Therapy
 Treatment Interruption
HAART Main Page Main New/Newsworthy Home Page
Last Update:  October 06, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Challenges
       

     Journal Papers, Abstracts, and Commentaries

 
A WEEK IN REVIEW FEATURED REPORT
 Initiation of therapy with a subcutaneously administered antiretroviral in treatment-experienced
HIV-infected patients: understanding physician and patient perspectives.
 Horne R, Cooper V, Fisher M.
AIDS Care. 2008 Oct;20(9):1029-38.
 Abstract
 
Selecting anti-HIV therapies based on a variety of genomic and clinical factors.
Rosen-Zvi M, Altmann A, Prosperi M, et al
Bioinformatics. 2008 Jul 1;24(13):i399-i406.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Antiretroviral therapy of late presenters with advanced HIV disease.
Battegay M, Fehr J, Flückiger U, Elzi L.
J Antimicrob Chemother. 2008 Apr 12
Abstract
 
New therapeutic options in protracted hiv-infected patients with virological failure.
Moreno Cuerda VJ, Rubio García R, Morales Conejo M.
Med Clin (Barc). 2008 Jan 26;130(2):66-70.
 Abstract
 
A randomized trial comparing the efficacy and tolerability of two HAART strategies at two
years in antiretroviral naive patients.
Mallolas J, Blanco JL, Pich J, et al 
Rev Clin Esp. 2007 Oct;207(9):427-432.
 Abstract

Antiretroviral treatment strategies and immune reconstitution in treatment-naïve HIV-infected
patients with advanced disease.
Soria A, Lazzarin A.
 J Acquir Immune Defic Syndr. 2007 Sep;46 Suppl 1:S19-30.
 Abstract
 
     Conference Reports, Abstracts, and Posters
 
 
POSTER
Intermediate (12 Months) and Long-term (6 Years) Cognitive Response to HAART in 2 |
Thai Cohorts
V Valcour P Sithinamsuwan, W Pumpradit, et al
 (15th CROI)
 PDF Poster     Abstract
 
The Effect of ART of Different Durations in Primary HIV Infection
N Pantazis, Giota Touloumi, P Vanhems, et al
(15th CROI)
Abstract

POSTER
 An Open-label Randomized Trial to Determine the Virologic and Immunologic Effects of
4-Weeks of Cyclosporine A Given in Combination with ART during Acute and Early Infection
M Markowitz, F Vaida, S Little ,et al
(15th CROI)
PDF Poster    Abstract
Once-Daily Versus Twice-Daily Regimens
       

     Conference Reports, Abstracts, and Posters

  POSTER
 Once-Daily Versus Twice-Daily Regimens: Which is Best for HIV Infected Patients?
B. VrijensL.Comté, E. Tousset J. Urquhart
(7th International Workshop on Clinical Pharmacology of HIV Therapy)
 PDF Poster
Simplification Therapy
       

     Journal Papers, Abstracts, and Commentaries

 
Potential risks and benefits of HIV treatment simplification: a simulation model of a
proposed clinical trial.
Schackman BR, Scott CA, Sax PE, et al
Clin Infect Dis. 2007 Oct 15;45(8):1062-70.
 Abstract

Benefits and concerns of simplification strategies in HIV-infected patients.
Negred E, Bonjoch A, Clotet B.
J Antimicrob Chemother. 2006 Jun 27;
 Abstract
 

     Conference Reports, Abstracts, and Posters

 
Improved treatment adherence associated with treatment simplification
 Baker D, Vale R, Doong N,  et al
 (4th IAS Conference)
 Abstract

Effect of Antiretroviral Simplified Regimens on Cellular HIV-DNA Levels-
G. D'ETTORRE M. CARNEVALINI, C. ANDREONI,  et al
 (45 ICAAC)
 Abstracts
Intensification Therapy
       

     Journal Papers, Abstracts, and Commentaries

 
Intensification of a suppressive HAART regimen increases CD4 counts and decreases
CD8+ T-cell activation.
Kolber MA, Saenz MO, Tanner TJ, et al
Clin Immunol. 2007 Nov 8;
Abstract
 
Evolution of resistance mutations pattern in HIV-1-infected patients during intensification
therapy with a boosted protease inhibitor.
Blanco JL, Biglia MA, Arnedo M, et al
AIDS. 2005 May 20;19(8):829-31.
 Abstract

Intensification of Antiretroviral Therapy Accelerates the Decay of the HIV-1 Latent
Reservoir and Decreases, But Does Not Eliminate, Ongoing Virus Replication.
 Ramratnam B, Ribeiro R, He T, et al
J Acquir Immune Defic Syndr. 2004
Abstract

Intensification and stimulation therapy for human immunodeficiency virus type 1
reservoirs in infected persons receiving virally suppressive highly active antiretroviral
therapy.
Kulkosky J, Nunnari G, Otero M, et al
J Infect Dis. 2002 Nov 15;186(10):1403-11.
Abstract
Mega-HAART
       

     Journal Papers, Abstracts, and Commentaries

  Mega-HAART: preliminary results and correlation with baseline resistance.
Rottmann C, Miller V, Staszewski S.
Antivir Ther. 1999;4 Suppl 3:93-4.
Abstract
General Outcome Studies
     
     Conference Reports, Abstracts, and Posters

  Outcome of Specific HAART Regimens Within and Outside a Randomized Controlled
Trial
A E. HANSEN, J. GERSTOFT , O. KIRK, et al
(45 ICAAC)
 Abstract
Treatment-Experienced Patients: General Strategies
       
     Journal Papers, Abstracts, and Commentaries
 
 
Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.
Lagnese M, Daar ES 
Expert Opin Pharmacother. 2008 Apr;9(5):687-700.
 Abstract
 
Treatment of Heavily Antiretroviral-Experienced HIV-Infected Patients.
Lunzen J.
 AIDS Rev. 2007 Oct-Dec;9(4):246-53.
 Abstract

Therapeutic options for treatment experienced patients: a focus on resistance testing
and optimizing background therapy.
Sax PE.
 AIDS Read. 2006 May;16(5):265-75, 277-8.
 Abstract
Advanced HIV Disease
       

     Journal Papers, Abstracts, and Commentaries

 
Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals
with advanced disease.
Manzardo C, Zaccarelli M, Agüero F, et al 
J Acquir Immune Defic Syndr. 2007 Sep;46 Suppl 1:S9-18.
Abstract

Management of advanced HIV disease: resistance, antiretroviral brain penetration
and malignancies.
Boffito M, Pillay D, Wilkins E. 
IntJ Clin Pract. 2006 Sep;60(9):1098-106.
Abstract

Effect of maintaining highly active antiretroviral therapy on AIDS events among
patients with late-stage HIV infection and inadequate response to therapy.
 Gandhi T, Wei W, Amin K, Kazanjian P.
 Clin Infect Dis. 2006 Mar 15;42(6):878-84.
 Abstract
Directly Administered Therapy
       
     Journal Papers, Abstracts, and Commentaries
 
  Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered
Antiretroviral Therapy.
 Maru DS, Bruce RD, Walton M, et al
AIDS Behav. 2007 Dec 18
Abstract
Intermittent Therapy
       
     Journal Papers, Abstracts, and Commentaries
 
 
Risk for Opportunistic Disease and Death after Reinitiating Continuous Antiretroviral
Therapy in Patients with HIV Previously Receiving Episodic Therapy: A Randomized Trial.
 The SMART Study Group.
Ann Intern Med. 2008 Sep 2;149(5):289-299.
 Abstract
 
Episodic Antiretroviral Therapy Increases HIV Transmission Risk Compared With Continuous Therapy:
Results of a Randomized Controlled Trial.
Burman W, Grund B, Neuhaus J,
J Acquir Immune Defic Syndr. 2008 Sep 2.
 Abstract

Modifications of HIV-1 DNA and Provirus-Infected Cells During 24 Months of Intermittent
Highly Active Antiretroviral Therapy.
Palmisano L, Giuliano M, Chiarotti F, et al
J Acquir Immune Defic Syndr. 2008 Mar 20
 Abstract
Discontinuation of Therapy
 

     Journal Papers, Abstracts, and Commentaries
Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients
with alcohol problems.
Kim TW, Palepu A, Cheng DM, et al
 AIDS Care. 2007 Sep;19(8):1039-47.
Abstract
 
Effects of Active Treatment Discontinuation in Patients With a CD4+ T-Cell Nadir Greater
Than 350 Cells/mm3: 48-Week Treatment Interruption in Early Starters Netherlands Study
(TRIESTAN).
Pogany K, Vanvalkengoed IG, Prins JM, et al
J Acquir Immune Defic Syndr. 2006 Dec 21;
Abstract
 
The Effects of Early Antiretroviral Therapy and Its Discontinuation on the HIV-Specific Antibody Response.
Killian MS, Norris PJ, Rawal BD, et al 
AIDS Res Hum Retroviruses. 2006 Jul;22(7):640-7
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US
HIV-infected patient cohort.
Yuan Y, L'italien G, Mukherjee J, Iloeje U.
 HIV Med. 2006 Apr;7(3):156-62.
 Abstract
 
Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US
HIV-infected patient cohort.
Yuan Y, L'italien G, Mukherjee J, Iloeje U.
 HIV Med. 2006 Apr;7(3):156-62.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Discontinuation of Antiretroviral Therapy in Patients with Chronic HIV Infection: Clinical,
Virologic, and Immunologic Consequences.
Mata RC, Viciana P, De Alarcon A, et al
AIDS Patient Care STDS. 2005 Sep;19(9):550-62.
 Abstract
 
Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral
therapy.
Fernandez Guerrero ML, Rivas P, Molina M, et al 
Clin Infect Dis. 2005 Aug 1;41(3):390-4.
 Abstract

It Is Safe to Stop Antiretroviral Therapy in Patients With Preantiretroviral CD4 Cell
Counts >250 cells/μL.
 Skiest DJ, Morrow P, Allen B, et al 
J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1351-135
 Abstract
 
     Conference Reports, Abstracts, and Posters
 
  A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Influence of Blips of Viral Load during HAART on Control of Viral Replication after Discontinuing
HAART
P Castro, A López, M Plana, et al
 (13 CROI)
 Poster
Prevention
       
     Journal Papers, Abstracts, and Commentaries
 
  FULL TEXT ARTICLE
 Potential Impact of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in
Resource-Limited Settings
Abbas UL, Anderson RM, Mellors JW.
PLoS ONE. 2007 Sep 19;2(9):e875.
 Paper

 
HAART Main Page Main New/Newsworthy Home Page

HAART Therapeutic Strategies